Our goal is to improve outcomes for cancer patients. We are interested in translational and basic cancer research involving antibodies. We develop novel cancer targeting antibodies and study their mechanisms of action in vitro and in mouse models.
Preclinical studies on therapeutic antibodies and antibody-conjugates
